Standard classifications describe what a company files as, not what it's a bet on. This is a curated list of the Pharma names in our US universe: the pure-plays, plus the larger companies for which Pharma is a real, reported driver rather than a passing mention. Each carries the same 0–100 quality-growth score used everywhere on the site (how it's built), and re-scores every trading day.
| # | Ticker | Company | Score |
|---|---|---|---|
| 1 | AZNPharmaceuticals | AstraZeneca PLC | 74.5 |
| 2 | LLYPharmaceuticals | Eli Lilly and Company | 69.8 |
| 3 | ABBVPharmaceuticals | AbbVie Inc. | 63.6 |
| 4 | BMYPharmaceuticals | Bristol-Myers Squibb Company | 61.5 |
| 5 | TAKPharmaceuticals | Takeda Pharmaceutical Company Limited | 60.0 |
| 6 | AMGNPharmaceuticals | Amgen Inc. | 57.5 |
| 7 | ZTSPharmaceuticals | Zoetis Inc. | 57.1 |
| 8 | NVSPharmaceuticals | Novartis AG | 53.4 |
| 9 | VTRSPharmaceuticals | Viatris Inc. | 50.1 |
| 10 | GSKPharmaceuticals | GSK plc | 49.1 |
| 11 | JNJPharmaceuticals | Johnson & Johnson | 45.7 |
| 12 | SNYPharmaceuticals | Sanofi | 43.0 |
| 13 | NVOPharmaceuticals | Novo Nordisk A/S | 42.5 |
| 14 | MRKPharmaceuticals | Merck & Co., Inc. | 37.3 |
| 15 | PFEPharmaceuticals | Pfizer Inc. | 29.5 |
The 15 members report under 2 different industries, which is exactly why no standard sector view groups them:
Average pillar scores across the 15 scored members, against every stock the model scores:
| Pillar | Pharma | Market | Read |
|---|---|---|---|
| Quality | 72.6 | 56.5 | 16.1 above |
| Growth | 58.6 | 58.8 | in line |
| Value | 42.1 | 44.8 | 2.7 below |
Pillars run 0–100 against sector peers. A low Value reading means the group is expensive relative to what it earns, not that the businesses are weak — for an early-stage theme that is the normal shape.
Scores across the group run from AZN at 74.5 down to PFE at 29.5, with a median of 53.4. A theme is a thesis, not a quality filter — membership says a company is exposed to Pharma, and the score says what the model makes of the business.
Across the 15 Pharmaceutical names with a reading, the median forward earnings estimate is roughly unchanged — +0.3% over 90 days, in line with the market (+0.3%). 7 of 15 are being revised up, 4 down.
Forward earnings estimates implied by price ÷ forward P/E, both captured at the same moment each trading day since June 2026, so a moving share price does not move these figures — only a changed forecast does. Estimate direction is not part of the Bull Rankings score. Biggest movers across the market →